Case File
efta-efta00920674DOJ Data Set 9OtherFrom: jeffrey epstein <jeevacation®gmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00920674
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: jeffrey epstein <jeevacation®gmail.com>
To: Boris Nikolic
Subject: Fwd: IMDx Introduces CE-marked Assay for VanR for European Market and ROW
Date: Wed, 28 Sep 2011 17:00:02 +0000
Sony for all the typos .Sent from my iPhone
Begin forwarded message:
ala
From: "Alice Jacobs" •
Date: September 28, 2011 6:45:04 PM GMT+02:00
To: "Denise Marston" <I
Cc: "Denise Marston"
Subject: IMDx Introduces CE-marked Assay for VanR for European Market and ROW
I hope that this message finds you well. I am pleased to announce that IMDx has launched its second CE-
marked product in two months for commercialization and distribution in Europe and ROW by Abbott for
detecting deadly health care infections, the IMDxm VanR for Abbott m2000' test (see below). This test
detects vancomycin-resistance genes associated with vancomycin resistant enterococci (VRE.)
Enterococci are normally found in the GI/GU tracts and can cause infections of the urinary tract, blood
stream, or in wounds from surgery or catheter insertions.
My best,
Alice
IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of
Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant
Enterococci
Cambridge, MA, September 21, 2011 — IntelligentMDx (IMDx) announced today that it has received CE-Mark
for its second automated molecular test for the Abbott FDA cleared m2000 instrument. The IMDxTM VanR for
Abbott m2000TM test accurately detects and distinguishes the vanA and vanB genes most commonly found in
vancomycin-resistant enterococci (VRE) in specimens from patients at risk for colonization or infection.
Detection of both the vanA and vanB genes allows for identification of a higher number of at-risk patients than
existing tests that only target the vanA gene. Like the recently introduced CE-marked IMDx C. difficile for
Abbott m2000 test, the IMDx VanR for Abbott m2000 test offers a high-throughput solution for early detection
of pathogens associated with common healthcare-associated infections.
VRE are bacteria which have become resistant to the antibiotic vancomycin, and are responsible for a variety
of healthcare-associated infections, including those of surgical wounds, urinary tract, and bloodstream. VRE
are transmitted through contact and are most often seen in hospitals due to the high prevalence of contaminated
surfaces and hand to hand contact.
The automated nature of the IMDx VanR for Abbott m2000 test allows laboratories to obtain results for up to
48 patient samples in less than 3 hours, and up to 94 patient samples in less than 4 hours. The IMDx VanR for
EFTA00920674
Abbott m2000 test exhibits high sensitivity and specificity when compared to traditional chromogenic agar
methods, with values of 96.4% and 98.0%, respectively.
"At IMDx, we have developed unique proprietary software analytic tools, enabling us to produce tests that are
sensitive, cost-effective, and rapid alternatives to existing culture-based screening methods for vancomycin-
resistant infections. We are proud to offer physicians the ability to make timely, informed decisions about
patient care in order to aid in preventing the spread of healthcare-associated infections." says Alice Jacobs,
MD, Chairman & CEO of IMDx.
About IMDx
Based in Cambridge, MA, IMDx (
is an innovative company that designs, develops
and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically
impactful and competitively differentiated for a range of disease areas for current and next generation systems,
including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology,
bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's
proprietary bioinformatics and product development processes allowing for the rapid design and development
of tests to meet clinical needs.
CONTACT: Renda Hawwa, +1-617-871-6417,
Alice A. Jacobs,
Chairman & CEO
Intellig entMDx
19 Blackstone Street
Cambridge, MA 02139
Phone:
Cell:
Fax:
Email:
Visit us at
The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any
review, retransmission, dissemination or other use of, or taking of any action in reliance upon, this information by persons or entities other than the
intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from all computers.
EFTA00920675
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
gmail.comPhone
+1-617-871-6417Related Documents (6)
DOJ Data Set 9OtherUnknown
From: Jeffrey Epstein <jeevacation®gmail.com>
2p
DOJ Data Set 9OtherUnknown
From: Jeffrey Epstein <[email protected]>
3p
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA01797210
0p
DOJ Data Set 10OtherUnknown
EFTA01818790
2p
DOJ Data Set 10CorrespondenceUnknown
EFTA Document EFTA01818790
0p
DOJ Data Set 9OtherUnknown
From: Boris Nikolic •t:
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.